-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。Ballは、2026年第1四半期の1株当たり利益(EPS)が前年同期比22.1%増の0.94ドルとなり、市場予想を0.10ドル上回りました。売上高は、販売量の増加とアルミニウム価格の転嫁により、16.3%増の36億ドルとなりました。比較可能な営業利益は9.9%増の3億8,700万ドルとなりましたが、売上高の伸びが鈍いことから、利益率の改善は依然として課題であることが分かります。販売量の増加はBallにとって有利な状況をもたらしており、特にEMEA地域は、持続可能性を重視したアルミニウム転換を反映し、営業利益が20.7%増と好調な業績を上げています。経営陣は、2026年のEPS成長率10%超、フリーキャッシュフロー9億ドル超というガイダンスを再確認しました。季節的な運転資金の変動によりレバレッジは3.39倍に上昇しましたが、8億ドルの株主還元目標を維持しながら、フリーキャッシュフロー目標の達成に向けて会社が前進するにつれて低下する見込みです。5億ドルの生産性向上プログラムが完了し、生産能力の最適化が効果を発揮することで、EBITDAマージンが2026年の15.3%から2027年には16.0%に改善すると予測しており、第2四半期と第3四半期の業績は、営業レバレッジが実現するより明確な証拠を示すものと期待しています。
Related Articles
American Electric Power CEO Says Speed to Market Key Issue in Load Connection
American Electric Power (AEP) CEO Bill Fehrman said Tuesday that speed to market is the main issue in efficiently connecting energy load to generation.In a Q1 earnings call, Fehrman said that, in particular, the performance and stakeholder approval process of PJM, the US mid-Atlantic grid operator, represents a major challenge."The current state of PJM's performance and stakeholder approval process does not give me great confidence that these issues will be resolved any time soon," Fehrman said on the call."In fact, if something is not done now, I expect we could still be having these same conversations in 10 years," he added.Expanding and strengthening the grid will ensure new generation resources can connect quickly, reliably, and affordably to serve the growing load, the CEO said.Price: $137.27, Change: $+2.61, Percent Change: +1.94%
MGE Energy Q1 Earnings, Revenue Rise
MGE Energy (MGEE) reported Q1 earnings Tuesday of $1.32 per diluted share, up from $1.14 a year earlier.One analyst polled by FactSet expected $1.13.Revenue for the three months ended March 31 was $242.7 million, up from $219 million a year earlier.Price: $80.48, Change: $+0.36, Percent Change: +0.46%
Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.